UB Paderborn / Katalog / Suche / in CDI

1 – 24 von 24

Sortiert nach

Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation

Frontiers in endocrinology (Lausanne), 2021-06, Vol.12, p.645617

Meier, Juris J

2021

Link zum Volltext

Verfügbarkeit prüfen

The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions

The lancet. Diabetes & endocrinology, 2016-06, Vol.4 (6), p.525-536

2016

Link zum Volltext

Verfügbarkeit prüfen

A meta‐analysis comparing clinical effects of short‐ or long‐acting GLP‐1 receptor agonists versus insulin treatment from head‐to‐head studies in type 2 diabetic patients

Diabetes, obesity & metabolism, 2017-02, Vol.19 (2), p.216-227

2017

Link zum Volltext

Verfügbarkeit prüfen

Incretin‐based glucose‐lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio‐vascular outcome trials

Diabetes, obesity & metabolism, 2017-09, Vol.19 (9), p.1327-1328

2017

Link zum Volltext

Verfügbarkeit prüfen

Comparison of Insulin-Treated Patients with Ambiguous Diabetes Type with Definite Type 1 and Type 2 Diabetes Mellitus Subjects: A Clinical Perspective

Diabetes and Metabolism Journal, 2023, 47(1), 195, pp.140-146

2023

Link zum Volltext

Verfügbarkeit prüfen

Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme

Diabetes, obesity & metabolism, 2020-08, Vol.22 (8), p.1263-1277

2020

Link zum Volltext

Verfügbarkeit prüfen

Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors

Circulation (New York, N.Y.), 2017-08, Vol.136 (9), p.849-870

2017

Link zum Volltext

Verfügbarkeit prüfen

Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon‐like peptide‐1 receptor agonists: A systematic analysis of published clinical trials

Diabetes, obesity & metabolism, 2017-03, Vol.19 (3), p.336-347

2017

Link zum Volltext

Verfügbarkeit prüfen

Risk of pancreatitis in patients treated with incretin-based therapies

Diabetologia, 2014-07, Vol.57 (7), p.1320-1324

2014

Link zum Volltext

Verfügbarkeit prüfen

Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial

Diabetes care, 2011-09, Vol.34 (9), p.2015-2022

2011

Link zum Volltext

Verfügbarkeit prüfen

Switching From Insulin Bolus Treatment to GLP-1 RAs Added to Continued Basal Insulin in People With Type 2 Diabetes on Basal-Bolus Insulin

Diabetes care, 2020-10, Vol.43 (10), p.2333-2335

2020

Link zum Volltext

Verfügbarkeit prüfen

Incretin-based therapies: where will we be 50 years from now?

Diabetologia, 2015-08, Vol.58 (8), p.1745-1750

2015

Link zum Volltext

Verfügbarkeit prüfen

MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?

European journal of endocrinology, 2019-12, Vol.181 (6), p.R211

2019

Link zum Volltext

Verfügbarkeit prüfen

Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short‐ and long‐acting glucagon‐like peptide‐1 receptor agonists in type 2 diabetes

Diabetes, obesity & metabolism, 2021-10, Vol.23 (10), p.2344-2353

2021

Link zum Volltext

Verfügbarkeit prüfen

Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes

Diabetes, obesity & metabolism, 2022-04, Vol.24 (4), p.684-692

2022

Link zum Volltext

Verfügbarkeit prüfen

Glucagon‐like peptide 1(GLP‐1) in biology and pathology

Diabetes/metabolism research and reviews, 2005-03, Vol.21 (2), p.91-117

2005

Link zum Volltext

Verfügbarkeit prüfen

Acute effects of linagliptin on intact and total glucagon‐like peptide‐1 and gastric inhibitory polypeptide levels in insulin‐dependent type 2 diabetes patients with and without moderate renal impairment

Diabetes, obesity & metabolism, 2022-05, Vol.24 (5), p.806-815

2022

Link zum Volltext

Verfügbarkeit prüfen

Glucagon-like peptide 1 and its derivatives in the treatment of diabetes

Regulatory peptides, 2005-06, Vol.128 (2), p.135-148

2005

Link zum Volltext

Verfügbarkeit prüfen

Glucose-lowering therapy in patients with cardiac comorbidities

Deutsche medizinische Wochenschrift (1946), 2015-04, Vol.140 (9), p.650

Meier, Juris J

2015

Link zum Volltext

Verfügbarkeit prüfen

Individualised incretin-based treatment for type 2 diabetes

The Lancet (British edition), 2010-08, Vol.376 (9739), p.393-394

2010

Link zum Volltext

Verfügbarkeit prüfen

Should antidiabetic treatment of type 2 diabetes in patients with heart failure differ from that in patients without?

European journal of heart failure, 2012-12, Vol.14 (12), p.1389-1400

2012

Link zum Volltext

Verfügbarkeit prüfen

Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2003, Vol.17 (2), p.93-102

2003

Link zum Volltext

Verfügbarkeit prüfen

The potential role of glucagon-like peptide 1 in diabetes

Current opinion in investigational drugs (London, England : 2000), 2004-04, Vol.5 (4), p.402

2004

Link zum Volltext

Verfügbarkeit prüfen

Incretins and their analogues as new antidiabetic drugs

Drug news & perspectives, 2003-09, Vol.16 (7), p.413-422

2003

Link zum Volltext

Verfügbarkeit prüfen

1 – 24 von 24

Suche als RSS-Feed

Aktive Filter

KollektionNature

ThemaMale

ThemaDiabetes Mellitus, Type 2 - Drug Therapy

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(15)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(24)

Sprache

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation

The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions

A meta‐analysis comparing clinical effects of short‐ or long‐acting GLP‐1 receptor agonists versus insulin treatment from head‐to‐head studies in type 2 diabetic patients

Incretin‐based glucose‐lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio‐vascular outcome trials

Comparison of Insulin-Treated Patients with Ambiguous Diabetes Type with Definite Type 1 and Type 2 Diabetes Mellitus Subjects: A Clinical Perspective

Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme

Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors

Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon‐like peptide‐1 receptor agonists: A systematic analysis of published clinical trials

Risk of pancreatitis in patients treated with incretin-based therapies

Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial

Switching From Insulin Bolus Treatment to GLP-1 RAs Added to Continued Basal Insulin in People With Type 2 Diabetes on Basal-Bolus Insulin

Incretin-based therapies: where will we be 50 years from now?

MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?

Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short‐ and long‐acting glucagon‐like peptide‐1 receptor agonists in type 2 diabetes

Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes

Glucagon‐like peptide 1(GLP‐1) in biology and pathology

Acute effects of linagliptin on intact and total glucagon‐like peptide‐1 and gastric inhibitory polypeptide levels in insulin‐dependent type 2 diabetes patients with and without moderate renal impairment

Glucagon-like peptide 1 and its derivatives in the treatment of diabetes

Glucose-lowering therapy in patients with cardiac comorbidities

Individualised incretin-based treatment for type 2 diabetes

Should antidiabetic treatment of type 2 diabetes in patients with heart failure differ from that in patients without?

Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus

The potential role of glucagon-like peptide 1 in diabetes

Incretins and their analogues as new antidiabetic drugs

Aktive Filter

Suchergebnisse filtern